<![CDATA[The ARTNet Podcast]]>Why do cancer treatments work for some patients at first, only to stop working later? In the premiere episode of the ARTNet Podcast, we speak with Dr. Jeffrey Tyner from Oregon Health & Science University about the complex biology behind acquired resistance to cancer therapies.

Dr. Tyner shares insights into how cancer cells adapt and survive treatment, the critical role of the tumor microenvironment, and why understanding resistance mechanisms is essential for developing more durable therapies. The conversation also explores how collaboration across the ARTNet Consortium is helping researchers connect data, models, and expertise to better understand cancer relapse and treatment failure.

From leukemia research to large-scale data sharing, this episode offers an inside look at one of the biggest challenges in modern oncology — and the scientific efforts underway to outsmart cancer before it fights back

]]>www.nciartnet.orgRiverside.fm (https://riverside.com)Sat, 18 Jul 2026 06:58:21 GMTMon, 11 May 2026 18:37:12 GMT60NCI ARTNet<p>Why do cancer treatments work for some patients at first, only to stop working later? In the premiere episode of the <a rel="noopener noreferrer nofollow" href="https://www.nciartnet.org?utm_source=chatgpt.com" target="_blank">ARTNet Podcast</a>, we speak with Dr. Jeffrey Tyner from Oregon Health &amp; Science University about the complex biology behind acquired resistance to cancer therapies.</p><p>Dr. Tyner shares insights into how cancer cells adapt and survive treatment, the critical role of the tumor microenvironment, and why understanding resistance mechanisms is essential for developing more durable therapies. The conversation also explores how collaboration across the ARTNet Consortium is helping researchers connect data, models, and expertise to better understand cancer relapse and treatment failure.</p><p>From leukemia research to large-scale data sharing, this episode offers an inside look at one of the biggest challenges in modern oncology — and the scientific efforts underway to outsmart cancer before it fights back</p>episodicNCI ARTNetvero.zhang@gmail.comno<![CDATA[Why Cancer Fights Back: A Conversation with Jeffrey Tyner ]]>Featuring

Jeffrey Tyner

Professor, Oregon Health & Science University

Principle Investigator, ARTNet AML U54 Center

Dr. Tyner is a leading researcher in cancer biology and therapeutic resistance, with a focus on acute myeloid leukemia (AML), functional precision oncology, and mechanisms of acquired resistance to targeted therapies.

Hosted by

David Goodrich

Professor, Roswell Park Comprehensive Cancer Center

ARTNet Coordinating and Data Management Center

Dr. Goodrich leads discussions exploring the science, collaboration, and translational impact of cancer resistance research across the ARTNet Consortium.

Episode Summary

The conversation explores the complexity of acquired resistance in cancer therapy, emphasizing the role of cell state and cellular plasticity in driving resistance mechanisms. Dr. Tyner discusses the challenges of studying dynamic resistance processes, the promise of targeting cell state plasticity to overcome therapeutic failure, and how resistance trajectories evolve over time.

The discussion also highlights the importance of identifying the optimal window for intervention and the growing role of collaborative science within the ARTNet Consortium in advancing cancer resistance research. Despite the complexity of the problem, the episode reflects a strong sense of optimism about the future of precision oncology and translational cancer research.

Key Takeaways

  • Acquired resistance is a dynamic and evolving process in cancer therapy
  • Cell state plasticity plays a central role in therapeutic resistance
  • Resistance mechanisms can differ across patients and tumor contexts
  • Understanding resistance trajectories may reveal new therapeutic opportunities
  • Collaborative research and data sharing are essential for advancing precision oncology

Chapters

  • 00:00 Introduction to ARTNet Consortium
  • 05:15 From Targeted Therapy to Tumor Complexity
  • 10:15 Understanding Acquired Resistance and Tumor Evolution
  • 19:50 Cell State Plasticity and Therapeutic Resistance
  • 24:05 Resistance Trajectories and Future Treatment Strategies
  • 29:00 The Future of Precision Oncology and the Role of ARTNet
]]>5c72123f-c11a-4c91-8a96-47165d20ac59Mon, 11 May 2026 19:12:39 GMT<p><b>Featuring</b></p><p>Jeffrey Tyner</p><p><i>Professor, Oregon Health &amp; Science University</i></p><p><i>Principle Investigator, </i><a rel="noopener noreferrer nofollow" href="https://www.nciartnet.org/en/members/aml/" target="_blank"><i>ARTNet AML U54 Center</i></a></p><p>Dr. Tyner is a leading researcher in cancer biology and therapeutic resistance, with a focus on acute myeloid leukemia (AML), functional precision oncology, and mechanisms of acquired resistance to targeted therapies.</p><p></p><p><b>Hosted by</b></p><p>David Goodrich</p><p><i>Professor, Roswell Park Comprehensive Cancer Center</i></p><p><a rel="noopener noreferrer nofollow" href="https://www.nciartnet.org/en/members/cdmc/" target="_blank"><i>ARTNet Coordinating and Data Management Center</i></a></p><p>Dr. Goodrich leads discussions exploring the science, collaboration, and translational impact of cancer resistance research across the ARTNet Consortium.</p><p></p><p><b>Episode Summary</b></p><p>The conversation explores the complexity of acquired resistance in cancer therapy, emphasizing the role of cell state and cellular plasticity in driving resistance mechanisms. Dr. Tyner discusses the challenges of studying dynamic resistance processes, the promise of targeting cell state plasticity to overcome therapeutic failure, and how resistance trajectories evolve over time.</p><p></p><p>The discussion also highlights the importance of identifying the optimal window for intervention and the growing role of collaborative science within the ARTNet Consortium in advancing cancer resistance research. Despite the complexity of the problem, the episode reflects a strong sense of optimism about the future of precision oncology and translational cancer research.</p><p></p><p><b>Key Takeaways</b></p><ul><li>Acquired resistance is a dynamic and evolving process in cancer therapy</li><li>Cell state plasticity plays a central role in therapeutic resistance</li><li>Resistance mechanisms can differ across patients and tumor contexts</li><li>Understanding resistance trajectories may reveal new therapeutic opportunities</li><li>Collaborative research and data sharing are essential for advancing precision oncology</li></ul><p></p><p><b>Chapters</b></p><ul><li>00:00 Introduction to ARTNet Consortium</li><li>05:15 From Targeted Therapy to Tumor Complexity</li><li>10:15 Understanding Acquired Resistance and Tumor Evolution</li><li>19:50 Cell State Plasticity and Therapeutic Resistance</li><li>24:05 Resistance Trajectories and Future Treatment Strategies</li><li>29:00 The Future of Precision Oncology and the Role of ARTNet</li></ul>no00:35:25Why Cancer Fights Back: A Conversation with Jeffrey Tyner full